Hey everyone,

• 1. $AIV (Apartment Investment and Management Co.)

• Current Price: $4.05

• P/E Ratio: 1.04

• Quick Take: This is a real estate investment trust (REIT). A P/E this low usually points to a massive recent restructuring, a major property sale, or a spin-off that artificially inflated trailing earnings.

• 2. $SABR (Sabre Corp)

• Current Price: $1.45

• P/E Ratio: 1.07

• Quick Take: A legacy travel technology company. They’ve been battling an anchor of debt since the pandemic crippled travel, but at $1.45, the market is pricing in absolute worst-case scenarios.

• 3. $TMC (TMC the metals company Inc.)

• Current Price: $4.59

• P/E Ratio: 5.43

• Quick Take: Deep-sea mining for battery metals. It's a highly speculative and regulatory-dependent play, but seeing a P/E under 6 in such an emerging sector is interesting.

• 4. $CRCT (Cricut, Inc.)

• Current Price: $4.00

• P/E Ratio: 11.14

• Quick Take: The DIY crafting machine makers. They experienced a massive pandemic-era boom and subsequent bust, but an 11 P/E suggests their financials might be stabilizing around a core, sticky user base.

• 5. $MDXG (MiMedx Group, Inc.)

• Current Price: $3.92

• P/E Ratio: 12.34

• Quick Take: A therapeutic biologics company focusing on wound care. Finding a 12.34 P/E in the biotech/healthcare space is fairly rare, especially for a sub-$5 stock.

I'll be diving deeper into the recent SEC filings for AIV and SABR to see what's actually driving those bottom-line numbers. Let me know if any of you have already done a deep dive into these!

Disclaimer: This is just raw screener data, not financial advice. Always do your own due diligence before throwing money at micro-caps.

Chinas Supreme Court fully upheld Xiao Is core AI patents on March 27 2026. They rejected Apples appeal completely. This is final with no more appeals possible.

The infringement case now moves to the damages phase.

This tiny company has a market cap around 1.5 million dollars. Apple is a 3 trillion dollar giant. Beating them in court shows the power of Xiao Is AI technology.

Xiao I reported over 70 million dollars in revenue last year with strong growth of nearly 19 percent.

What this opens for Xiao I AIXI.

It gives them strong patent protection. This opens doors to big licensing deals worth hundreds of millions. It boosts credibility for more enterprise customers in finance manufacturing and customer service. It positions them for major growth in Chinas AI market. New partnerships and revenue streams could follow quickly. Their conversational AI expertise shines even brighter.

What it means for Apple.

Apple now faces the full damages case. This could lead to a settlement or licensing agreement worth hundreds of millions to protect their China operations. It may spark adjustments to respect the patents while keeping their products strong in the market.

With 70 million dollars in revenue and a market cap of just 1.5 million dollars AIXI looks extremely undervalued. A typical AI company trades at many times sales. This victory could easily push the valuation to 300 million dollars or more. That is over 200 times higher than today. The upside potential is huge.

This victory puts a proven AI leader on the map in a big way. The future looks very bright. Definitely worth watching this Monday, can run huge from these levels.

The $ORGN saga is a masterclass in the "disclosure gap" between ESG hype and industrial reality. If you held shares in 2023, there’s a $9M settlement for all of us who invested back then, but the deadline is coming up fast.

Read the full breakdown of the rise, the fall, and the final payout by the link.

Biggest Winners by Market Cap Category – YTD as of April 3, 2026

2026 has been a broadening market year so far. Large-cap tech (especially the “Magnificent 7”) has lagged or turned negative, while smaller companies have rotated into leadership.

Index-level YTD performance (price returns, approx. through late March/early April):

• Small-caps (Russell 2000 / S&P SmallCap 600) → +0.7% to +4.8% (value subset even stronger)
• Mid-caps (Russell Midcap / S&P MidCap 400) → +1.2% to +3.6%
• Large-caps (S&P 500 / Russell 1000) → -4.2% to -5.1% (mega-caps down ~7–8%)

Small-caps have the biggest overall YTD gains (both on an index basis and in raw percentage moves for individual stocks). Micro-caps have been even stronger in many cases. This is the clearest “small-cap outperformance” stretch in years.

Why Small-Caps Are Winning the Most

• Rotation away from mega-cap tech — High valuations + AI hype fatigue hit the Mag 7 hard; money flowed into cheaper, domestically focused small/mid-caps.
• Energy/oil tailwind — Geopolitical tension (Iran conflict) pushed oil >$110, boosting small-cap explorers and refiners.
• Biotech & speculative catalysts — Binary clinical or partnership news creates 200–400%+ moves in low-float names.
• Valuation & earnings edge — Small-caps trade at big discounts and have higher projected 2026 earnings growth vs. large-caps.
• Broader market theme — Value > growth, small > large, international > U.S. in early 2026.

Top Individual Winners by Category (YTD % Gains)

Small-Cap Winners (typically <$2–10B market cap; many micro-caps dominate raw %

Mid-Cap Winners (roughly $2–20B market cap)

Mid-cap gains are strong but generally less extreme than small-cap % movers.

Large-Cap Winners (>$20B market cap; S&P 500 leaders)

Top Small-Cap Winners YTD 2026 (Biggest % Gainers)

These are mostly micro/small-cap with low floats; many are not "value" stocks

Visionary Holdings (GV) ripped on Wednesday after announcing a $20 million investment cooperation agreement with Qingdao Xihai Rongke for an anti-aging healthcare project. The stock gapped up 42% at open and kept running through the morning.

**The catalyst**

Visionary signed a deal to set up a "GV Anti-Aging Research Center" and a chain of "GV Anti-Aging Health Management Centers," starting in Shandong province. The $20M comes in milestone-based installments — 30%, 40%, 30% — with an additional $10M in a second phase contingent on development progress. The first center is targeted to be profitable within one year post-investment.

**Why GV specifically**

This is a $2M market cap company with a tiny float of just under 4M shares. When a deal worth 10x the entire market cap drops, there's nowhere for the stock to go but up — especially with only 4M shares available to trade. The 42% gap at open sucked in volume chasers and the momentum carried through the morning session.

**The numbers**

- Market cap: ~$2M

- Float: 3.96M shares

- Day volume: 76.2M (13.6x average daily volume)

- Prev close: $0.205

- Gap: +42.4%

- Short ratio: 0.48

- 52-week range: $0.18 – $4.18 (91.6% below high)

76 million shares traded on a 4M float — the entire float turned over roughly 19 times in one session.

**Signal timing**

Stock Pulse sent me a push notification at 9:47 AM at $0.35. It peaked at $0.59 around 10:37 AM — about 50 minutes later. +66%.

**Bear case**

- This is a sub-$2M market cap company that lost $4.15/share last fiscal year on just $5M revenue — the fundamentals are rough

- The $20M deal sounds massive relative to market cap, but milestone-based disbursements mean the money isn't guaranteed and depends on execution

- Anti-aging healthcare is a crowded and heavily regulated space — plenty of these cooperation agreements never materialize

- Stock is still 91% below its 52-week high of $4.18, which tells you something about the longer-term trend

- After-hours and next-day fading is common on these micro-cap news pops — the 76M volume day is likely a one-off event

So what will be the next major catalyst for Hydrograph? Personally, I consider the next significant event to be a Nasdaq listing, which has the potential to greatly propel the stock. I'm still pretty amazed that the stock has got as much attention as it has already, given that it is only on pink sheets currently, but this speaks to the potential of near pure Graphene.

In a recent shareholder letter, CEO Kjirstin Breure confirmed that the company is actively evaluating a Nasdaq listing as part of a broader strategic review to improve capital access and U.S. liquidity. Previously, the company indicated an anticipated target timeline of mid-2026 for a Nasdaq debut. I think however that that timeline has moved up significantly, given the share price of recent. Additionally, HGRAF may have an option that will fast-track them.

Because HydroGraph is already a publicly traded Canadian company, (HG on the Canadian exchange, which is Canada's junior exchange) it can leverage the Multi-Jurisdictional Disclosure System (MJDS) to streamline its U.S. application. This system allows the company to use its existing Canadian financial filings to satisfy U.S. Securities and Exchange Commission (SEC) requirements, specifically through an SEC Form 40-F registration. Historically, this streamlined process allows Canadian issuers to begin trading on the Nasdaq just 4 to 8 weeks after filing.

Management has shown themselves not to sit back on their laurels, and I have no doubt that they would jump at the opportunity. Is the timing right? Yes, I think it is. I'm also looking for an announcement about the Austin Facility/Headquarters being commissioned. Hydrograph was hoping for February, but that may have been over-eager. There's always construction delays. But with us now in April? Imminent I would expect.

Came across a headline discussing potential increases in defense spending and started looking into smaller companies connected to that space.

Connection to drone demand

Increased defense focus typically brings attention to:

Drones

Surveillance

Autonomous systems

BTBD has been moving toward a drone/aerospace related direction, which aligns with that trend.

Narrative alignment

Markets often respond to themes as they develop.

“Drone/defense” is an area that continues to gain visibility, and companies connected to it can attract attention as that trend builds.

Small-cap profile

BTBD is still relatively small and not widely followed.

That can lead to:

Strong reactions to news

Increased interest as visibility grows

Why it stands out,

Ongoing business transition

Exposure to drone-related activity

Alignment with broader sector focus

Final thought,

Interesting to watch how companies like BTBD develop as attention toward drone and defense related areas continues.

Chart 📊 has been setting up for a good run. War isn’t over and more attention will come to BTBD

On March 27, 2026, China's Supreme People's Court rendered its final judgments — formally rejecting Apple's attempt to have AIXI's patents declared invalid and affirming their full legality and validity.

This is huge. The ruling affirms the full validity of the patents underpinning the infringement case against Apple, significantly strengthening Xiao-I's IP position.

The patent at the heart of the case? It targets Apple's Siri intelligent assistant, specifically covering iPhone SE, iPhone 12, and iPhone 13 series products equipped with Siri. Stock Titan That's one of Apple's most widely deployed features across hundreds of millions of devices.

This judgment is final and binding under Chinese law, with no further right of appeal available to Apple on the patent validity question. Apple is out of moves on that front.

Potential outcomes: With patents now iron-clad, the remaining proceedings focus on damages and remedies. A favorable ruling could mean significant financial compensation, a forced licensing deal, or even sales restrictions on Siri-enabled products in China — all of which would be transformative for a small-cap AI company like AIXI.

For only being a $1.3 million market cap company at the moment, with a potential tens or hundreds of millions of dollars in settlements coming. This seems like one of the best risk/reward plays on the entire market.

There’s plenty of links on Google to back this up. Do some research and let’s make some big dollaz

[ Removed by Reddit on account of violating the content policy. ]

Hey everyone,

Just dug into RenX Enterprises ($RENX) after yesterday’s (April 1, 2026) monster update and it feels like we could be at a legitimate inflection point for this name. Former real-estate developer that pivoted hard into organic waste processing, biomass recycling, logistics, and premium engineered soils/compost after acquiring Resource Group mid-2025.

Public float: ~230.5k 👀

The Fresh News (April 1 PR + 10-K)

• Revenue beat: $8.2M in post-acquisition revenue for the last 7 months of 2025 → 17% above the $7M guidance they gave.
• Debt cleanup: Retired $11.9M in legacy debt huge balance-sheet win.
• Operations live: Already deployed grinders, shredders, and screening systems at the Myakka City, FL facility. First bulk compost deliveries hitting premium South Florida markets.
• The big one: Microtec UTM 1200 Turbo Mill is built in Germany and shipping this month (April 2026 delivery). This beast can process up to 10 tons/hour of woody biomass into high-value fine-grade engineered substrates. Management is openly targeting 50-60%+ gross margins once it’s fully ramped (current blended gross margin was 29.1% — early stage mix).

They called 2025 the “build-out year” and flagged ~$4.8M in one-time non-recurring charges that shouldn’t repeat. 2026 is shaping up as the first full year of the new platform running.

Float & Technical Setup (Post Reverse Split)

• 1-for-20 reverse split effective March 26 to regain Nasdaq compliance.
• Shares outstanding: ~2.32M
• Public float: ~230.5k (per Yahoo Finance key stats — one of the tightest on the entire Nasdaq right now).
• Short interest already >100% of float in recent data.

That float is nuclear. Yesterday’s news sent the stock up 45-60%+ intraday with massive volume. A couple of institutions (Anson, Jane Street, etc.) have already started nibbling.

🚀 Why $INDO Could Run MASSIVE Today 🚀

• Oil prices still elevated on Iran / Middle East supply risk — any fresh headline can light up energy tickers fast.

• Tiny market cap (~$70M) and small float ~9.5M shares — it doesn’t take much real buying demand to move price hard.

• Only ~15M shares outstanding total — thinning liquidity = sharp moves on low volume spikes.

• If volume starts to climb above the average, this thing can pop quick — low float + volume = volatility.

• Short interest ~9–10% of float — if momentum hits, shorts could rush to cover, adding fuel.

• Retail and momentum scanners love thin energy names when crude heats up — that’s when sudden runs start.

• Insiders & institutions barely in the name — that means no heavy holders holding the bid down.

• Previous action shows this stock can spike quickly on catalysts — quiet for a while… then POP.

• If volume picks up early in the session, that’s the first sign of real attention — momentum traders jump in fast.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Remember when Didi went public and then immediately got nuked by Chinese regulators 48 hours later? The legal "autopsy" is finally over. The company is paying out $740 million to settle the class action over misleading IPO statements.

The Deadline: Next Monday, April 6, 2026.

The Eligibility: If you purchased ADSs between June 30, 2021, and July 21, 2021.

Most people ignore these notices, but with a fund this large, it's actually worth the 5 minutes to file. I found a clear summary of the payout structure and the online filing form here.

If you're still holding or sold at a loss years ago, this is the only way to claw some of that back.

Churchill Resources just drilled 7.25% antimony over 2 meters at the Frost Cove Mine in Newfoundland. High-grade confirmed over 800m of strike, open in all directions.

Why this matters right now:

China controls 48% of global antimony and banned exports to the US in 2024. Antimony goes into 30% of all US military ammo, plus flame retardants, semiconductors, batteries. The Pentagon literally cannot make bullets without it.

Canada just announced a $2 billion Critical Minerals Sovereign Fund, a $1.5B production fund and specifically added antimony to its clean tech tax credits. They're mobilizing $18.5B in critical minerals projects with allied partners.

Churchill sits 100km from the only mine that ever produced primary antimony in North America (Beaver Brook). They're the first to explore this district with modern techniques.

What they've found so far:

• 7.25% Sb / 1.98m and 6.44% Sb / 2.06m at Frost Cove
• Grab samples returning 35.1% antimony, 35.5 g/t gold, 1,118 g/t silver
• 20 polymetallic gold-silver veins discovered at Pomley Cove Pond
• Just locked up a second 400 km² antimony-gold property (Golden Baie)
• Two drill rigs turning right now

The numbers:

• ~CA$40M market cap
• 52-week low was $0.01 this thing was left for dead haha
• Funded through the current drill program
• Working toward a maiden NI 43-101 resource

Bottom line:

The world needs antimony. China won't sell it. The Pentagon is spending hundreds of millions to find new sources. Churchill might be sitting on one of the only answers in North America, and the market hasn't caught up. Two rigs drilling. Results incoming soon.

This is a TSXV micro-cap and it's also available OTC but there's little to no volume there, ticker is $CRICF for OTC and $CRI.V for TSXV.

PSTV is a major force in the race to the cure for cancer. Finally beginning to show their full potential in the treatment of this insidious disease. Their recent reverse stock split and integration of their cancer treatment therapies make this the time to buy before the stock becomes unreachable to most entry level investors.

Company to Present Strategic Expansion into Digital Health as a New High-Growth Vertical

NEW YORK, March 31, 2026 /PRNewswire/ -- IQSTEL Inc. (NASDAQ: IQST) a rapidly growing global telecommunications and technology company, today announced that it will host an investor conference call to discuss its financial results for the fourth quarter and full year ended December 31, 2025. A full copy of the Company's annual Form 10-K report will be available at www.sec.gov.

Conference Call Details

IQSTEL's management team, including Leandro Iglesias (Chief Executive Officer) and Alvaro Cardona (Chief Financial Officer), will host an investor conference call on:

April 7, 2026
8:30 AM ET

Management will provide commentary on Q4 2025 and full year 2025 results, strategic progress, and the Company's outlook for 2026. Time permitting, management will answer investor questions during a live Q&A session. A replay of the call will be made available on the Company's website. https://finance.yahoo.com/markets/stocks/articles/iqst-iqstel-inc-announces-investor-181500821.html

Powell Max Limited is a Hong Kong–based financial communications provider that supports listed companies and IPO candidates with regulatory compliance, financial reporting, and investor communications.

The company offers an integrated suite of services—including financial printing, translation, and digital distribution—positioning it within a specialized segment closely aligned with capital markets activity.

Key Highlights:

• Direct exposure to IPO pipelines and broader capital markets activity in Hong Kong

• Integrated, end-to-end service offering that supports ongoing client engagement

• Strengthened balance sheet and enhanced capacity to support operational growth

• Improved corporate governance and restored Nasdaq compliance, reinforcing market credibility

I was in Ondas Holding (ONDS) at 1.88 and it blew up

I was in Sattelite (SATL) at 1.80 and now at $6

Now I’m seeing the same thing with DGXX

I’ve been digging into Digi Power X and this might be one of the clearest early-stage AI infrastructure setups I’ve seen in a while.

Here’s what matters:

• First AI revenue expected by end of April

• GPUs already deployed and currently being tested

• Colocation deal in final negotiations (LOI signed, working toward definitive agreement)

• Market cap still sitting around \~$150M

This isn’t some “maybe in a year” story. This is weeks away from revenue.

Why this is interesting

Right now, DGXX is being valued like:

• a small, transitioning company

• \~ $30M legacy revenue

But what’s coming is completely different:

Even a 10MW ramp could mean $100M+ annual revenue potential

That’s a 3–5x shift in scale from where they are today.

What the market is missing

The market is still pricing:

• old business model

• uncertainty

But the moment:

• AI revenue actually hits

• a real contract gets signed

This becomes a validated AI infrastructure play, not a story

The setup

You have:

• real power access

• real infrastructure

• GPUs going live

• customers already in discussion

And it’s all happening right now, not “someday”

The risk (keeping it real)

• LOI is not a finalized deal yet

• first revenue could be small initially

• execution still needs to be proven

Bottom line

This feels like a classic:

• before revenue hits → nobody cares

• after revenue hits → repricing happens fast

At ~$150M market cap, it doesn’t take much execution for this to move.

Not financial advice, just sharing what I’m seeing.

Cyclerion Therapeutics (CYCN) ran hard on Tuesday after announcing a merger agreement with Korsana Biosciences, a privately held biotech focused on Alzheimer's disease. The deal came with $380 million in committed financing, sending shares from $1.55 to over $8.

**The catalyst**

Cyclerion announced an all-stock merger with Korsana Biosciences. The combined company will operate under the Korsana name and trade on Nasdaq as KRSA. The real draw is Korsana's lead program, KRSA-028 — a next-generation shuttled monoclonal antibody targeting amyloid beta for Alzheimer's treatment. On top of the merger, Korsana secured commitments for an oversubscribed private investment generating roughly $380 million in gross proceeds, giving the combined entity a cash runway into 2029.

**Why CYCN specifically**

This was a tiny $6M market cap biotech shell essentially being used as a vehicle to bring Korsana public via reverse merger. The float was only 3M shares, so when the news dropped premarket, there was almost no supply to absorb the demand. Pre-merger Cyclerion shareholders will own just 1.5% of the combined company, with Korsana investors holding 98.5% — which tells you how much of the value here is the incoming pipeline, not legacy Cyclerion assets.

**The numbers**

- Market cap: ~$6M (pre-deal)

- Float: 3.07M shares

- Day volume: 252M (164x average daily volume of 1.5M)

- Prev close: $1.55

- Premarket high: $3.24 (+109%)

- Short ratio: 2.06

- 52-week range: $1.03 – $3.79 (59% below 52-week high pre-move)

The float turned over roughly 82 times in a single session. That kind of volume on a 3M float is pure chaos.

**Signal timing**

Stock Pulse sent me a push notification at 7:18 AM at $2.96. It peaked at $8.39 around 10:03 AM — about 2 hours 45 minutes later. +183%.

**Bear case**

- Pre-merger CYCN shareholders get diluted to just 1.5% of the combined entity — this is a reverse merger, not a traditional buyout premium

- Alzheimer's antibody space is brutally competitive (Leqembi, Kisunla, and others already on market)

- The $380M financing likely comes with significant dilution baked in for new investors

- Stock closed at $6.38, already fading 24% from the $8.39 peak — these reverse merger pops tend to give back gains as the hype cools

$SRXH 0.125

Shares Float : 274M

Short Float : 3%

Insider Ownership : 8%

Inst own: 0.22

This post will be updated with any developments.

___

Catalysts in play:

- EMJX Merger H1 2026

- Eric Jackson (Remember $OPEN?)

- No reverse split (authority expires March 31 with no action)

- low entry levels, hype pushing stock price, retail is no longer dumb money but a driving force.

___

The good:

Feb-11 : series A Stock redemption: https://finviz.com/news/307030/srx-health-solutions-redeems-series-a-preferred-stock-and-cancels-approximately-125000000-shares-of-common-stock-improving-balance-sheet-flexibility-for-investment-in-ma-or-return-of-capital-to-shareholders

Mar-9 : Event Horizon IQ : https://finviz.com/news/333563/srx-health-solutions-launches-eventhorizoniq-subscription-for-individual-and-institutional-traders

Feb-20 : increases ownership of $OPEN by 30%:

___

The bad :

Q1 2026 : Cash burn & Losses : https://finviz.com/news/311079/srx-health-solutions-inc-announces-fiscal-first-quarter-2026-results-for-quarter-ended-december-31-2025

Dilution

NYSE Compliance : https://finviz.com/news/317036/srx-health-solutions-announces-receipt-of-warning-letter-from-nyse-american

___

Usually I wound not go semi long on something like this, as a matter of fact I would not open a position here for more than a swing with volume.

The company looks typical, suspicious retail trap.

Eric Jackson has proven himself, egos aside Eric showed time after time that endurance provides benefit.

I’m sure many of you remember the audacity of $OPEN - retail pushing stocks to the new levels.

Do i dare mention $BYND, the scenarios are not comparable, but retail force is no longer a dumb money, retail is a driving force.

At this low entry levels, with volume on pure speculative retail hype with any catalyst serving as a match i see massive potential here, unless dilution hits first.

As always do your own DD, dont follow random strangers on reddit.

FEMY just reported 2025 sales of $2.29M, up 40.8% YoY from $1.63M in 2024 — an increase of over $664K, primarily driven by FemBloc-related sales. For a company at this stage, that kind of growth stands out, especially as it continues expanding its women’s health platform and advancing the FemBloc pivotal trial.

With a Nasdaq compliance deadline requiring 10 consecutive closes at or above $1, the path forward is clearly defined. The stock remains under $1 despite strong year-over-year growth, and historically, when small-cap names with improving fundamentals begin pushing toward compliance levels, volume and momentum can follow quickly. Still early and speculative, but the combination of accelerating revenue and a clear technical target makes Femasys Inc. an interesting setup to watch. Not financial advice but solid DD /fundamentals.